Third‐line therapy for overactive bladder in the elderly: Nuances and considerations
Sign Up to like & getrecommendations! Published in 2022 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24965
Abstract: Overactive bladder (OAB) disproportionally affects older adults in both incidence and severity. OAB pharmacotherapy is often problematic in the elderly due to polypharmacy, adverse side effect profiles and contraindications in the setting of multiple comorbidities,… read more here.
Keywords: third line; line therapy; overactive bladder;
An analysis of factors that influence patient preference of third‐line therapy for overactive bladder
Sign Up to like & getrecommendations! Published in 2022 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.25046
Abstract: Patients with overactive bladder (OAB) refractory to first‐ and second‐line therapy may pursue third‐line therapies, including intradetrusor onabotulinum toxin‐A (BTX), peripheral tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM). The factors that influence patient preference… read more here.
Keywords: line therapy; third line; factors influence; overactive bladder ... See more keywords
Percutaneous tibial neuromodulation initial therapy compliance and subsequent third‐line treatment patterns
Sign Up to like & getrecommendations! Published in 2024 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.25448
Abstract: Percutaneous Tibial Neuromodulation (PTNM) is used to treat Overactive Bladder (OAB). This analysis summarizes patient adherence to PTNM treatment and examines trends of other third‐line therapy use during and after PTNM. read more here.
Keywords: treatment; tibial neuromodulation; percutaneous tibial; third line ... See more keywords
Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-01956-2
Abstract: Cabazitaxel has played an important role in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC); however, several types of sequential therapy against mCRPC have been performed in routine clinical practice. The objective of… read more here.
Keywords: third line; cabazitaxel; line; treatment patients ... See more keywords
Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-017-0593-9
Abstract: IntroductionThe purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the… read more here.
Keywords: third line; line; treatment; line treatment ... See more keywords
Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01889-2
Abstract: The survival of patients with relapsed small cell lung cancer (SCLC) has achieved little progress in the last several decades. ALTER1202 confirmed the efficacy and safety of anlotinib as a third- or further-line option for… read more here.
Keywords: cost effectiveness; cost; sclc; third line ... See more keywords
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-02899-6
Abstract: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard first- and second-line treatment for advanced ALK+ non-small cell lung cancer (NSCLC). We evaluated outcomes in patients with ALK+ NSCLC receiving third-line ALK TKI versus… read more here.
Keywords: treatment; line treatment; line; third line ... See more keywords
15: Identifying barriers to third‐line therapy: a patient‐centered approach to refractory overactive bladder
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Obstetrics and Gynecology"
DOI: 10.1016/j.ajog.2019.01.044
Abstract: 15 Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder A. Davenport, S. Stark, A. Quian, D. Sheyn, J. Mangel Case Western Reserve University, Cleveland, OH, Obstetrics & Gynecology, MetroHealth Medical Center,… read more here.
Keywords: medicine; third line; therapy; refractory ... See more keywords
S01. Third-line antiepileptic treatment outcomes in refractory status epilepticus
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2018.04.361
Abstract: Introduction Although there has been multiple studies and several clinical trials (ex ESETT) addressing the use of second-line agents in the treatment of benzodiazepine refractory status epilepticus, there has been little research concerning third-line agents… read more here.
Keywords: status epilepticus; treatment; third line; line ... See more keywords
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "ESMO open"
DOI: 10.1016/j.esmoop.2022.100422
Abstract: BACKGROUND Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a poor prognosis. No efficacious treatment options are currently available for patients with advanced metastatic disease with disease progression to standard etoposide, doxorubicin, cisplatin… read more here.
Keywords: second third; adrenocortical carcinoma; treatment; line ... See more keywords
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.02.026
Abstract: OBJECTIVES Despite intensive research, the therapeutic options in extensive-stage small cell lung cancer (SCLC) are still limited. Data from routine clinical practice, so-called "real-world data", are centrally important to assess and improve the standard of… read more here.
Keywords: second third; third line; line; treatment ... See more keywords